Navigation Links
Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
Date:11/2/2009

ing cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States and Europe.

About PEGINTRON

PEGINTRON is indicated for use in combination with REBETOL (ribavirin) for the treatment of chronic hepatitis C in patients 3 years of age and older with compensated liver disease.

The following points should be considered when initiating therapy with PEGINTRON in combination with REBETOL:

(1) These indications are based on achieving undetectable HCV RNA after treatment for 24 or 48 weeks and maintaining a Sustained Virologic Response (SVR) 24 weeks after the last dose.

(2) Patients with the following characteristics are less likely to benefit from re-treatment after failing a course of therapy: previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, and genotype 1 infection.

(3) No safety and efficacy data are available for treatment of longer than one year.

PEGINTRON is also indicated for use alone for the treatment of chronic hepatitis C in patients with compensated liver disease previously untreated with interferon alpha and who are at least 18 years of age.

The following points should be considered when initiating therapy with PEGINTRON alone: Combination therapy with REBETOL is preferred over PEGINTRON monotherapy unless there are contraindications to, or significant intolerance of, REBETOL. Combination therapy provides substantially better response rates than monotherapy.

Important Safety Information on PEGINTRON

WARNING: RISK OF SERIOUS DISORDERS AND RIBAVIRIN-ASSOCIATED EFFECTS

Alpha interferons, including PEGINTRON, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 The Competitive Intelligence (CI) ... marketplace changes. CI leaders who adjust will succeed, and ... a new Best Practices, LLC study CI leaders from ... including: - Use secondary research whenever possible ... - Internal staff who are creative thinkers ...
(Date:8/29/2014)... Aug. 29, 2014   Mast Therapeutics, Inc. ... announced today that Santosh Vetticaden, Chief Medical Officer ... Company, for personal reasons, in mid-September.  Edwin ... of Aires Pharmaceuticals, which Mast acquired earlier this ... the Company,s interim Chief Medical Officer.  Dr. Parsley ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
(Date:8/30/2014)... New Delhi, India (PRWEB) August 30, 2014 ... has introduced low cost SEO service for small businesses. ... businesses or start-ups cannot afford costly search engine optimization ... the budget of small businesses into account. , ... executive said, “We have introduced this low cost SEO ...
(Date:8/30/2014)... After offering hyperbaric oxygen therapy ... past several years, Dr. Roy Schmidt and the ... a scholarship program for veterans who have been ... held this summer to discuss veterans’ needs ( ... shed light on the large number of veterans ...
(Date:8/30/2014)... Richmond, VA (PRWEB) August 30, 2014 Seniors ... several articles recently that focus on Alzheimer’s Disease, Dementia, ... recently revealed to the public of being diagnosed with the ... his latest movie, “I’ll Be Me”. The movie, out ... life while focusing on his diagnosis of the disease – ...
(Date:8/30/2014)... Continuing to meet the skin health ... the addition of a new doctor and office in ... leading-edge skin care in Grand Rapids since 1980 is ... a doctor, my passion is making sure my patients ... Dermatology, I’m better able to focus on my patients ...
(Date:8/30/2014)... Hastings and Hastings, a qualified team ... Arizona is pleased to report having saved a client ... among many cases where Hastings and Hastings has tailored ... a greater portion of their settlement or recovery. The ... positive solution for Arizona car accident victims is achievable ...
Breaking Medicine News(10 mins):Health News:RBSEO Services Introduces Low Cost SEO Service for Small Businesses 2Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:Expanding Care at the Forefront of Dermatology 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2
... the car is essential. According to researchers in Japan the majority ... in the back used seat belts.We already know that using a ... crash among those wearing one. What has not been clear is ... in the front of the car. ,A team at ...
... discovered microscopic organism found in river bed can ... warned. The single-celled microbe was first identified in ... experiencing memory loss and difficulties with concentration, attention ... a stinging or burning sensation to the skin ...
... Sacks, chair of the DASH (Dietary Approaches to Stop ... good diet pattern are as effective in decreasing blood ... could lead to a 20% decrease in the prevalence ... prevalence of strokes. ,The DASH-Sodium study included ...
... male chromosome as a marker, researchers studying eight cross-gender ... that the body can actively reshape the heart after ... heart cannot repair itself and the finding has implications ... the body works to repair a damaged heart much ...
... major Dr Reddy’s Laboratories will continue to aggressively challenge patents ... a 180-day marketing exclusivity to its generic Omeprazole 40 mg ... indicated for the treatment of duodenal and gastric ulcers. ... the US. The loss of marketing exclusivity is a setback ...
... hope for hearing impairment. A new hearing device that is ... a more conventional aid. Doctors say that there's now a ... hearing aid transmits sound through the eardrum, and may produce ... giving the wearer the feeling of talking within a barrel. ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: